Our vision at ISBT would not have become reality without the huge commitment and active contribution from them.
Roche provides diagnostic tests and automation platforms used worldwide to improve the safety of blood products, increase laboratory efficiency, diagnose disease, monitor response to therapy and identify gene-based factors that may aid in treatment selection. For more information about Roche, please visit: www.roche.com.
Abbott is a health care company that is devoted to discovering new medicines, new technologies and new ways to manage health. The products span the continuum of care, from nutritional products laboratory diagnostics through medical devices and pharmaceutical therapies. For more information about Abbott, please visit their website: www.abbott.com.
Immucor plays a role in making blood transfusions safe for patients around the world. They market a complete line of traditional immunohematology reagents and fully automated instruments as well as data management software. For more information about Immcuor, please visit: www.immucor.com.
With over 30 years of experience developing, manufacturing and commercializing blood-grouping reagents for the global transfusion diagnostics market, Quotient is focused on providing high quality, high value immunohematology products to hospitals and blood banks around the world. Quotient is nearing the commercialization of MosaiQ™, a next generation automation platform for transfusion diagnostics. For more information about Quotient, please visit: www.quotientbd.com
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today.
Please visit: www.terumobct.com
Ortho Clinical Diagnostics provides trusted products and services to the clinical laboratory and immunohematology communities. For more information about Ortho Clinical Diagnostics please visit: www.orthoclinicaldiagnostics.com
Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. They accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. For more information about Grifols, please visit: www.diagnostic.grifols.com.
bioMérieux has been a global leader in in vitro diagnostics for more than 50 years, They have always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Today, in more than 150 countries through 43 subsidiaries and a large network of distributors, bioMérieux provides diagnostic solutions that improve patient health and ensure consumer safety. Please visit: http://www.biomerieux.com/ for more information.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. For more information please visit: http://cerus.com/
DiaSorin develops, produces and distributes immunoreagent kits for clinical diagnostics. By making tests available that can provide guidance in making clinical decisions, DiaSorin has contributed to improving the delivery of health care and reducing its costs. For more information about DiaSoring, please visit: www.diasorin.com/en.
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange. For more information about Sysmex Corporation and its affiliate companies, please visit http://www.sysmex.co.jp/en/.
As for the product information, please visit the following web sites of each region;
EMEA : https://www.sysmex-europe.com/n/products.html
Americas : https://www.sysmex.com/US/en/Products/Pages/Sysmex-Product-Overview.aspx
Asia Pacific: https://www.sysmex-ap.com/products/
Glycorex’s unique technology that bio-specifically selects and removes blood group antibodies has opened up revolutionary treatments and has been used clinically for the last 20 years to enable more than 5,000 blood group incompatible transplantations. The company’s technology to treat blood is applied in several health care settings and a new unique product variant has recently been launched designed to increase availability of blood plasma by specifically reducing the blood group antibodies in donated blood plasma – a way to make ‘universal blood plasma’. Glycosorb® has the potential to provide significant improvements in logistics and accessibility. www.glycorex.com
Their valued support enables ISBT to continue facilitating knowledge about transfusion medicine and promoting a safe blood supply.
All levels of Corporate partners enjoy priority allocation at ISBT congresses for exhibition space and satellite symposia. Platinum and Gold partners have the opportunity to meet with members of the ISBT Executive committee and to work with ISBT when appropriate on educational activities.
We offer four levels of partnership:
Dowload the Corporate Partnership Brochure to learn more about how we work with partners. For further information please contact our Marketing Coordinator Beatriz Galindo